Business and Finance

In today’s Pharma Pulse, Johnson & Johnson commits over $1 billion to a new biomanufacturing site in Pennsylvania, while Hims & Hers enters a $1.15 billion agreement to acquire Australian telehealth leader Eucalyptus.

A policy change allowing approval of some new drugs based on one adequate and well-controlled study could accelerate development timelines, while raising questions about evidentiary standards and downstream supply chain planning.

The logistics provider has launched a temperature-controlled network with new dedicated capacity and aviation routes designed to enhance the transport of time-critical pharmaceuticals and biologics, responding to the rising demand for reliable, compliant cold-chain logistics.

In the first part of his Pharma Commerce video interview, John Stanford, Incubate’s executive director, explains how third round of CMS drug selections brings physician-administered medicines under price controls for the first time, intensifying debate over provider reimbursement and investment in small-molecule therapies.

In today’s Pharma Pulse, the FDA shifts its stance on Moderna’s mRNA flu vaccine after an initial rejection, while Eli Lilly secures a major licensing deal for a promising anti-inflammatory antibody.

The online pharmacy is collaborating with a digital health provider to combine direct-to-patient GLP-1 dispensing with virtual clinical support, highlighting evolving supply chain and regulatory considerations in obesity care.

In the final part of his Pharma Commerce video interview, Dan Chancellor, Norstella’s vice president of thought leadership, shares that companies facing the largest revenue gaps from looming patent expirations—including Bristol Myers Squibb—could be poised for increased dealmaking as they look to rebuild growth pipelines.

A 2026 industry survey finds mounting pressure from PBMs, federal pricing reforms, and compliance scrutiny, as manufacturers increase automation and AI investment to manage expanding gross-to-net exposure.

In the second part of his Pharma Commerce video interview, Dan Chancellor, Norstella’s vice president of thought leadership, suggests that 2026 pharma M&A may fall short of last year’s $220 billion total—potentially featuring fewer but larger, high-value acquisitions driven by competitive bidding.

In today’s Pharma Pulse, the Senate tackles the regulatory red tape driving physician burnout, while Edwards Lifesciences ends its anti-copycat policy to settle European Commission antitrust concerns.

In the first part of his Pharma Commerce video interview, Dan Chancellor, Norstella’s vice president of thought leadership, explains that despite a looming loss of exclusivity affecting up to $300 billion in drug sales by 2032, pharma dealmaking is expected to remain steady in 2026, as companies pursue acquisitions to close persistent portfolio growth gaps.

The new platform offers coupon-driven discounts on dozens of high-cost brand name drugs, while raising new questions about eligibility, access, and how savings are applied.

A landmark FTC settlement requires Express Scripts to overhaul formulary and rebate practices, boosting price transparency in the process.

The acquisition expands ORBIS’ manufacturing capacity and technical expertise in reusable plastic pallets, lids, and trays, enabling faster design, prototyping, and production for pharma and broader supply chain applications.

The deal strengthens Körber’s SAP supply chain and digital manufacturing consulting portfolio, extends its global footprint, and creates Körber Stellium to deliver end-to-end supply chain and software solutions.

For the first time, CMS has released negotiated prices for high-cost drugs covered under both Medicare Part D and Part B, naming 15 new negotiation targets and signaling continued efforts to rein in prescription drug spending.

The acquisition strengthens M&D’s specialty portfolio, broadens access to plasma-derived therapies, and supports phased integration focused on regulatory compliance.

How direct-to-patient programming can transform the prescription journey for patients and manufacturers alike.

In today’s Pharma Pulse, Congress races to secure funding, while Novavax nets a half-billion-dollar validation of its non-aluminum vaccine technology.

In today’s Pharma Pulse, over 200 health groups denounce childhood vaccine schedule cuts, GSK acquires RAPT Therapeutics, and BD partners with ten23 health to scale large-volume injectors.

The partnership aims to speed commercialization, reduce risk, and enable large-volume biologics to shift from IV to subcutaneous delivery.

In the fourth part of his Pharma Commerce video interview, Alan Balch, PhD, CEO of the Patient Advocate Foundation and the National Patient Advocate Foundation, outlines the financial pressures that make sustained safety net protections a healthcare imperative.

In today’s Pharma Pulse, the FDA and EMA synchronize on AI standards, a potential divide in pricing strategy occurs, and BoomRx launches a needle-free nanoemulsion for weight loss.

In the third part of his Pharma Commerce video interview, Alan Balch, PhD, CEO of the Patient Advocate Foundation and the National Patient Advocate Foundation, points out that from employer-paid premiums to Medicare and Medicaid subsidies, the US system relies on layered financial support to keep coverage within reach—underscoring how few individuals can realistically pay the full cost of care or insurance on their own.

In today’s Pharma Pulse, Novartis calls for a shift from "cost-containment" to structural reform, hospital mergers hit their lowest point in 15 years, and new data warns of "cost shocks" driven by copay accumulators.